Switch theme
Sign up to access all valuation multiples
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
2020
13.5K+
LTM Revenue $4.9B
LTM EBITDA $884M
$8.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bausch & Lomb has a last 12-month revenue of $4.9B and a last 12-month EBITDA of $884M.
In the most recent fiscal year, Bausch & Lomb achieved revenue of $3.4B and an EBITDA of $420M.
Bausch & Lomb expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bausch & Lomb valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.9B | $3.4B | XXX | XXX | XXX |
| Gross Profit | $1.6B | $1.8B | XXX | XXX | XXX |
| Gross Margin | 54% | 52% | XXX | XXX | XXX |
| EBITDA | $349M | $420M | XXX | XXX | XXX |
| EBITDA Margin | 12% | 13% | XXX | XXX | XXX |
| Net Profit | $4.2M | -$182M | XXX | XXX | XXX |
| Net Margin | 0% | -5% | XXX | XXX | XXX |
| Net Debt | $1.5B | $3.0B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Bausch & Lomb's stock price is CAD 17 (or $12).
Bausch & Lomb has current market cap of CAD 5.9B (or $4.2B), and EV of CAD 12.2B (or $8.5B).
See Bausch & Lomb trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.5B | $4.2B | XXX | XXX | XXX | XXX | $0.63 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Bausch & Lomb has market cap of $4.2B and EV of $8.5B.
Bausch & Lomb's trades at 1.7x LTM EV/Revenue multiple, and 9.6x LTM EBITDA.
Analysts estimate Bausch & Lomb's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Bausch & Lomb and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $8.5B | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 20.2x | XXX | XXX | XXX |
| P/E | -18.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -206.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBausch & Lomb's NTM/LTM revenue growth is 3%
Bausch & Lomb's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Bausch & Lomb's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Bausch & Lomb's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Bausch & Lomb and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 16% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 57% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bausch & Lomb acquired XXX companies to date.
Last acquisition by Bausch & Lomb was XXXXXXXX, XXXXX XXXXX XXXXXX . Bausch & Lomb acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Bausch & Lomb founded? | Bausch & Lomb was founded in 2020. |
| Where is Bausch & Lomb headquartered? | Bausch & Lomb is headquartered in Canada. |
| How many employees does Bausch & Lomb have? | As of today, Bausch & Lomb has 13.5K+ employees. |
| Who is the CEO of Bausch & Lomb? | Bausch & Lomb's CEO is Mr. Brenton L. Saunders. |
| Is Bausch & Lomb publicy listed? | Yes, Bausch & Lomb is a public company listed on TSE. |
| What is the stock symbol of Bausch & Lomb? | Bausch & Lomb trades under BLCO ticker. |
| When did Bausch & Lomb go public? | Bausch & Lomb went public in 2022. |
| Who are competitors of Bausch & Lomb? | Similar companies to Bausch & Lomb include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Bausch & Lomb? | Bausch & Lomb's current market cap is $4.2B |
| What is the current revenue of Bausch & Lomb? | Bausch & Lomb's last 12-month revenue is $4.9B. |
| What is the current EBITDA of Bausch & Lomb? | Bausch & Lomb's last 12-month EBITDA is $884M. |
| What is the current EV/Revenue multiple of Bausch & Lomb? | Current revenue multiple of Bausch & Lomb is 1.7x. |
| What is the current EV/EBITDA multiple of Bausch & Lomb? | Current EBITDA multiple of Bausch & Lomb is 9.6x. |
| What is the current revenue growth of Bausch & Lomb? | Bausch & Lomb revenue growth between 2023 and 2024 was 16%. |
| Is Bausch & Lomb profitable? | Yes, Bausch & Lomb is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
